IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

64,666

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

December 31, 2021

Conditions
Atrial FibrillationStroke
Interventions
BEHAVIORAL

Early Patient-Level and Provider-Level Educational Intervention

"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."

BEHAVIORAL

Delayed Provider-Level Educational Intervention

Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.

Trial Locations (4)

19422

Aetna, Inc., Blue Bell

40202

Humana Healthcare Research, Inc., Louisville

02169

Harvard Pilgrim Health Care, Quincy

02451

OptumInsight, Inc, Waltham

All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

collaborator

Clinical Trials Transformation Initiative

OTHER

collaborator

Humana Inc.

INDUSTRY

collaborator

Aetna, Inc.

INDUSTRY

collaborator

OptumInsight Life Sciences, Inc.

UNKNOWN

collaborator

Food and Drug Administration (FDA)

FED

lead

Harvard Pilgrim Health Care

OTHER

NCT03259373 - IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation | Biotech Hunter | Biotech Hunter